RETRACTED: LncRNA DLX6-AS1 Contributes to Epithelial–Mesenchymal Transition and Cisplatin Resistance in Triple-negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis

Abstract

Keywords

DLX6-AS1 miR-199b-5p paxillin triple-negative breast cancer ceRNA

At the request of the Journal Editor and Publisher, the following articles have been retracted

Zhang T, Zhang L, Han D, Tursun K, Lu X. Circular RNA hsa_Circ_101141 as a competing endogenous RNA facilitates tumorigenesis of hepatocellular carcinoma by regulating miR-1297/ROCK1 pathway. Cell Transplantation. 2020;29. doi:10.1177/0963689720948016.

Du C, Wang Y, Zhang Y, Zhang J, Zhang L, Li J. LncRNA DLX6-AS1 contributes to epithelial–mesenchymal transition and cisplatin resistance in triple-negative breast cancer via modulating miR-199b-5p/paxillin axis. Cell Transplantation. 2020;29. doi:10.1177/0963689720929983.

Wan Q, Chen Q, Cai D, Zhao Y, Wu X. OTUB2 promotes homologous recombination repair through stimulating Rad51 expression in endometrial cancer. Cell Transplantation. 2020;29. doi:10.1177/0963689720931433.

Li W, Yang X, Shi C, Zhou Z. Hsa_circ_002178 promotes the growth and migration of breast cancer cells and maintains cancer stem-like cell properties through regulating miR-1258/KDM7A axis. Cell Transplantation. 2020;29:. doi:10.1177/0963689720960174.

Liu G, Guo W, Rao M, Qin J, Hu F, Li K. circRNA hsa_circ_104566 sponged miR-338-3p to promote hepatocellular carcinoma progression. Cell Transplantation. 2020;29. doi:10.1177/0963689720963948.

Li J, Yu Z, Zhu Q, Tao C, Xu Q. hsa_circ_102559 acts as the sponge of miR-130a-5p to promote hepatocellular carcinoma progression through regulation of ANXA2. Cell Transplantation. 2020;29. doi:10.1177/0963689720968748.

Li J, Yang Y, Xu D, Cao L. hsa_circ_0023409 accelerates gastric cancer cell growth and metastasis through regulating the IRS4/PI3K/AKT pathway. Cell Transplantation. 2021;30. doi:10.1177/0963689720975390.

Wang Y, Yin L. LINC00461 promoted endometrial carcinoma growth and migration by targeting MicroRNA-219-5p/cyclooxygenase-2 signaling axis. Cell Transplantation. 2021;30. doi:10.1177/0963689721989616.

Wu J, Wang X, Yuan X, et al. Kinesin family member C1 increases temozolomide resistance of glioblastoma through promoting DNA damage repair. Cell Transplantation. 2021;30. doi:10.1177/0963689721991466.

Hui Y, Yang Y, Li D, et al. LncRNA FEZF1-AS1 modulates cancer stem cell properties of human gastric cancer through miR-363-3p/HMGA2. Cell Transplantation. 2020;29. doi:10.1177/0963689720925059.

After an internal investigation, Sage has become aware that the submissions contain indicators of third-party involvement. Due to concerns around author contributions to the articles, as well as concerns around the integrity of the research process, Sage and the Journal Editor retract the articles.

The authors have been informed of this decision using the email addresses provided at submission.

References

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: CA-Cancer J Clin. 2018;68(6):394–424.

Gray

Rasanayagam

Engel

Rizzo

. State of the evidence 2017: an update on the connection between breast cancer and the environment. Environ Health. 2017;16(1):94–94.

Waks

Winer

. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.

Qin

Yan

Zhang

. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res. 2019;38(1):195–195.

Oualla

Elzawahry

Arun

Reuben

Woodward

Eldin

Lim

Mellas

Ueno

Fouad

. Novel therapeutic strategies in the treatment of triple-negative breast cancer. Ther Adv Med Oncol. 2017;9(7):493–511.

Zhang

Liu

Ren

Zhu

Fan

Zhang

. Investigation of paclitaxel-carboplatin one-cycle neoadjuvant chemotherapy plus trastuzumab in HER2-positive breast cancer. Eur J Gynaecol Oncol. 2018;39(6):899–902.

Gohr

Hamacher

Engelke

Kassack

. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer. 2017;17(1):711.

Anastasiadou

Jacob

Slack

. Non-coding RNA networks in cancer. Nat Rev Cancer. 2017;18(1):5–18.

Sahu

Singhal

Chinnaiyan

. Long noncoding RNAs in cancer: from function to translation. Trends Cancer. 2015;1(2):93–109.

10.

Bartonicek

Maag

JLV

Dinger

. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer. 2016;15(1):43.

11.

de Oliveira

Oliveira

Mathias

Pedroso

Lemos

Salviano Silva

Jucoski

Lobo-Alves

Zambalde

Cipolla

Gradia

. Long non-coding RNAs in cancer: another layer of complexity. J Gene Med. 2019;21(1):e3065.

12.

Feng

Clark

Mady

Shah

Kohtz

. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Gene Dev. 2006;20(11):1470–1484.

13.

Zhang

Tang

Yao

. LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through wnt signaling. Biochem Bioph Res Co. 2018;507(1-4):260–266.

14.

Zhang

Chen

Xue

Wang

Zhao

Han

Zhang

Hou

. Prognostic significance of micrornas in glioma: a systematic review and meta-analysis. Biomed Res Int. 2019;2019.

15.

Zeng

Tang

Wei

Liu

Long noncoding

RNA

DLX6-AS1 promotes renal cell carcinoma progression via miR-26a/PTEN axis. Cell cycle (Georgetown, Tex.). 2017;16(22):2212–2219.

16.

Tang

Zheng

. Long noncoding RNA DLX6-AS1 promotes liver cancer by increasing the expression of WEE1 via targeting miR-424-5p. J Cell Biochem. 2019;120(8):12290–12299.

17.

Feng

Clark

Mady

Shah

Kohtz

. The Evf-2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and functions as a Dlx-2 transcriptional coactivator. Gene Dev. 2006;20(11):1470–1484.

18.

Shen

Xie

Wang

Yan

Chen

, et al. Identification of novel long non-coding RNAs in triple-negative breast cancer. Oncotarget. 2015;6(25):21730–21739.

19.

Wang

Gao

. Long noncoding RNAs (lncRNAs) in triple negative breast cancer. J Cell Physiol. 2017;232(12):3226–3233.

20.

Bautista

Gomez

Miranda

Dehesa

Villarrealgarza

Avilamoreno

Arrieta

. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer. Clin Epigenetics. 2018;10(1):106.

21.

Tang

Sang

Zhang

Feng

. LncRNA PVT1 regulates triple-negative breast cancer through KLF5/beta-catenin signaling. Oncogene. 2018;37(34):4723–4734.

22.

Han

Hao

Dong

Shen

Pang

. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway. Toxicol Appl Pharm. 2018;359:55–61.

23.

Lin

Xing

Liang

Han

Wang

Hawke

Wang

Zhang

Wei

, et al. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol. 2016;18(2):213–224.

24.

Zhang

. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1. Gene. 2019;686:1–7.

25.

Tian

Jiang

Huang

Zheng

. Comprehensive analysis of dysregulated lncRNAs, miRNAs and mRNAs with associated ceRNA network in esophageal squamous cell carcinoma. Gene. 2019;696:206–218.

26.

Zhang

Tang

Yao

. LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling. Biochem Bioph Res Co. 2018;507(1-4):260–266.

27.

Zhao

Yang

Chen

Bai

Dun

Chen

Wang

. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma. Cancer Cell Int. 2015;15(1):48–48.

28.

Heery

Finn

Cuffe

Gray

. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 2017;9(4):38.

29.

Tian

Kuang

Wen

Guo

. Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells. Exp Ther Med. 2019;17(6):4715–4722.

30.

Olea-Flores

Juárez-Cruz

Mendoza-Catalán

Padilla-Benavides

Navarro-Tito

. Signaling pathways induced by leptin during epithelial-mesenchymal transition in breast cancer. Int J Mol Sci. 2018;19(11):3493.

31.

Ling

Watt

Banerjee

Newsted

Truesdell

Adams

Sidhu

Craig

AWB

. A novel immunotherapy targeting MMP-14 limits hypoxia, immune suppression and metastasis in triple-negative breast cancer models. Oncotarget. 2017;8(35):58372–58385.

32.

Reilly

EAO

Gubbins

Sharma

Tully

Guang

MHZ

Weinergorzel

Mccaffrey

Harrison

Furlong

Kell

. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clinical. 2015;3:257–275.

33.

Lee

Djamgoz

MBA

. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–122.

34.

Garridocastro

Lin

Polyak

. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176–198.

35.

Deng

Zhang

Shi

Guo

Ding

Tang

Hou

. Role of long non-coding RNA in tumor drug resistance. Tumor Biol. 2016;37(9):11623–11631.

36.

Wang

Guan

Qian

Cao

Teng

. LncRNA UCA1 in anti-cancer drug resistance. Oncotarget. 2017;8(38):64638–64650.

37.

Seo

Choi

Joo

Lee

. MiR-199a/b-5p Inhibits lymphangiogenesis by targeting discoidin domain receptor 1 in corneal injury. Mol Cells. 2018;41(2):93–102.

38.

Zhang

Qian

Yang

Zhu

Zhou

Wang

Liu

Yan

. MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma. Gene. 2018;659:22–28.

39.

Duan

Wang

Yin

. MiR-199b-5p promotes tumor growth and metastasis in cervical cancer by down-regulating KLK10. Biochem Bioph Res Co. 2018;503(2):556–563.